{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:33:21Z","timestamp":1715992401476},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,8,19]],"date-time":"2007-08-19T00:00:00Z","timestamp":1187481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1007\/s11912-007-0053-9","type":"journal-article","created":{"date-parts":[[2007,8,18]],"date-time":"2007-08-18T11:06:11Z","timestamp":1187435171000},"page":"391-398","source":"Crossref","is-referenced-by-count":14,"title":["Mantle cell lymphoma: Evolving novel options"],"prefix":"10.1007","volume":"9","author":[{"given":"Andre","family":"Goy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,8,19]]},"reference":[{"key":"53_CR1","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","volume":"106","author":"K. Fu","year":"2005","unstructured":"Fu K, Weisenburger DD, Greiner TC, et al.: Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005, 106:4315\u20134321.","journal-title":"Blood"},{"key":"53_CR2","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","volume":"23","author":"V. Fernandez","year":"2005","unstructured":"Fernandez V, Hartmann E, Ott G, et al.: Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005, 23:6364\u20136369.","journal-title":"J Clin Oncol"},{"key":"53_CR3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2003-12-4175","volume":"104","author":"H. Kohlhammer","year":"2004","unstructured":"Kohlhammer H, Schwaenen C, Wessendorf S, et al.: Genomic DNA-chip hybridization in t(11, 14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 2004, 104:795\u2013801.","journal-title":"Blood"},{"key":"53_CR4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","volume":"3","author":"A. Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A, et al.: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185\u2013197.","journal-title":"Cancer Cell"},{"key":"53_CR5","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","volume":"107","author":"T. Katzenberger","year":"2006","unstructured":"Katzenberger T, Petzoldt C, Holler S, et al.: The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006, 107:3407.","journal-title":"Blood"},{"key":"53_CR6","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/modpathol.3880448","volume":"14","author":"E. Schlette","year":"2001","unstructured":"Schlette E, Lai R, Onciu M, et al.: Leukemic mantle cell lymphoma: clinical and pathologic spectrum of twenty-three cases. Mod Pathol 2001, 14:1133\u20131140.","journal-title":"Mod Pathol"},{"key":"53_CR7","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","volume":"107","author":"C. Pott","year":"2006","unstructured":"Pott C, Schrader C, Gesk S, et al.: Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006, 107:2271\u20132278.","journal-title":"Blood"},{"key":"53_CR8","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2003-05-1383","volume":"102","author":"D. Kienle","year":"2003","unstructured":"Kienle D, Krober A, Katzenberger T, et al.: VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003, 102:3003\u20133009.","journal-title":"Blood"},{"key":"53_CR9","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V108.11.814.814","volume":"108","author":"E. Hoster","year":"2006","unstructured":"Hoster E, Dreyling N, Unterhalt M, et al.: A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 2006, 108:814.","journal-title":"Blood"},{"key":"53_CR10","first-page":"49","volume":"12","author":"J.O. Armitage","year":"1998","unstructured":"Armitage JO: Management of mantle cell lymphoma. Oncology (Williston Park) 1998, 12:49\u201355.","journal-title":"Oncology (Williston Park)"},{"key":"53_CR11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","volume":"97","author":"J.E. Romaguera","year":"2003","unstructured":"Romaguera JE, Medeiros LJ, Hagemeister FB, et al.: Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003, 97:586\u2013591.","journal-title":"Cancer"},{"key":"53_CR12","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","volume":"20","author":"O.M. Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS, et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J. Clin Oncol 2002, 20:1288\u20131294.","journal-title":"J. Clin Oncol"},{"key":"53_CR13","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","volume":"16","author":"I.F. Khouri","year":"1998","unstructured":"Khouri IF, Romaguera J, Kantarjian H, et al.: Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803\u20133809.","journal-title":"J Clin Oncol"},{"key":"53_CR14","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"J.E. Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, et al.: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013\u20137023.","journal-title":"J Clin Oncol"},{"key":"53_CR15","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood.V104.11.1388.1388","volume":"104","author":"B.S. Kahl","year":"2004","unstructured":"Kahl BS, McGovern, Blank J, et al.: Phase II study of modified hyper-CVAD with rituximab maintenance for previously untreated mantle cell lymphoma: A Wisconsin Oncology Network Study [abstract]. Blood 2004, 104:1388.","journal-title":"Blood"},{"key":"53_CR16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.1998.16.2.579","volume":"16","author":"D. Decaudin","year":"1998","unstructured":"Decaudin D, Bosq J, Tertian G, et al.: Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998, 16:579\u2013583.","journal-title":"J Clin Oncol"},{"key":"53_CR17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10428190109097721","volume":"42","author":"B.J. Cohen","year":"2001","unstructured":"Cohen BJ, Moskowitz C, Straus D, et al.: Cyclophosphamide\/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001, 42:1015\u20131022.","journal-title":"Leuk Lymphoma"},{"key":"53_CR18","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R. Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064\u20133071.","journal-title":"Blood"},{"key":"53_CR19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-006-0193-2","volume":"86","author":"D.S. Ritchie","year":"2007","unstructured":"Ritchie DS, Seymour JF, Grigg AP, et al.: The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 2007, 86:101\u2013105.","journal-title":"Ann Hematol"},{"key":"53_CR20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","volume":"16","author":"F. Lefrere","year":"2002","unstructured":"Lefrere F, Delmer A, Suzan F, et al.: Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002, 16:587\u2013593.","journal-title":"Leukemia"},{"key":"53_CR21","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","volume":"21","author":"I.F. Khouri","year":"2003","unstructured":"Khouri IF, Lee MS, Saliba RM, et al.: Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma. J Clin Oncol 2003, 21:4407\u20134412.","journal-title":"J Clin Oncol"},{"key":"53_CR22","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"M.J. Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, et al.: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 2005, 23:3383\u20133389.","journal-title":"J Clin Oncol"},{"key":"53_CR23","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1200\/jco.2006.24.18_suppl.7560","volume":"24","author":"A. Zelenetz","year":"2006","unstructured":"Zelenetz A, Noy A, Pandit-Taskar M, et al.: Sequential radioimmunotherapy with tositumomab\/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions [abstract]. J Clin Oncol Proc ASCO 2006, 24:7560","journal-title":"J Clin Oncol Proc ASCO"},{"key":"53_CR24","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/jco.2006.24.18_suppl.7503","volume":"24","author":"M. Smith","year":"2006","unstructured":"Smith M, Chen H, Gordon L, Horning S: Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patents with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499) [abstract]. J Clin Oncol 2006, 24:7503.","journal-title":"J Clin Oncol"},{"key":"53_CR25","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.V104.11.2632.2632","volume":"104","author":"Y. Oki","year":"2004","unstructured":"Oki Y, Pro B, Depassand E, et al.: A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract]. Blood 2004, 104:2632.","journal-title":"Blood"},{"key":"53_CR26","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","volume":"99","author":"A.K. Gopal","year":"2002","unstructured":"Gopal AK, Rajendran JG, Petersdorf SH, et al.: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002, 99:3158\u20133162.","journal-title":"Blood"},{"key":"53_CR27","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/jco.2007.25.18_suppl.8032","volume":"25","author":"F. Morschhauser","year":"2007","unstructured":"Morschhauser F, Leonard JP, Fayad L, et al.: Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I\/II results [abstract]. J Clin Oncol 2007, 25:8032.","journal-title":"J Clin Oncol"},{"key":"53_CR28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V106.11.230.230","volume":"106","author":"A. Advani","year":"2005","unstructured":"Advani A, Gin\u00e9 E, Gisselbrecht C, et al.: Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin\u2019s lymphoma (NHL) [abstract]. Blood 2005, 106:230.","journal-title":"Blood"},{"key":"53_CR29","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.V106.11.1504.1504","volume":"108","author":"R. Advani","year":"2005","unstructured":"Advani R, Furman R, Rosenblatt J, et al.: A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin\u2019s lymphoma [abstract]. Blood 2005, 108:1504.","journal-title":"Blood"},{"key":"53_CR30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.V106.11.489.489","volume":"106","author":"Y. Younes","year":"2005","unstructured":"Younes Y, Vose J, Zelenetz A, et al.: Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed\/refractory non-Hodgkin\u2019s lymphoma (NHL) [abstract]. Blood 2005, 106:489.","journal-title":"Blood"},{"key":"53_CR31","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","volume":"11","author":"S.S. Neelapu","year":"2005","unstructured":"Neelapu SS, Kwak LW, Kobrin CB, et al.: Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 2005, 11:986\u2013991.","journal-title":"Nat Med"},{"key":"53_CR32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.coi.2006.01.011","volume":"18","author":"K.S. Peggs","year":"2006","unstructured":"Peggs KS, Quezada SA, Korman AJ, Allison JP: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006, 18:206\u2013213.","journal-title":"Curr Opin Immunol"},{"key":"53_CR33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J. Adams","year":"2004","unstructured":"Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4:349\u2013360.","journal-title":"Nat Rev Cancer"},{"key":"53_CR34","first-page":"2291","volume":"22","author":"A. Goy","year":"2003","unstructured":"Goy A, East K, Mesina F, et al.: Report of a phase II study of proteasome inhibitor bortezomib in patients with relapsed or refractory indolent and aggressive B-cell lymphomas [abstract]. J Clin Oncol Proc ASCO 2003, 22:2291.","journal-title":"J Clin Oncol Proc ASCO"},{"key":"53_CR35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"O.A. O\u2019Connor","year":"2005","unstructured":"O\u2019Connor OA, Wright J, Moskowitz C, et al.: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676\u2013684.","journal-title":"J Clin Oncol"},{"key":"53_CR36","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2004-03-0850","volume":"104","author":"S. Strauss","year":"2004","unstructured":"Strauss S, Maharaj L, Jim Stec J, et al.: Phase II clinical study of bortezomib (VELCADE\u00ae) in patients (pts) with relapsed \/ refractory non-Hodgkin\u2019s lymphoma (NHL) and Hodgkin\u2019s disease (HD) [abstract]. Blood 2004, 104:1386.","journal-title":"Blood"},{"key":"53_CR37","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood.V104.11.608.608","volume":"104","author":"A. Belch","year":"2004","unstructured":"Belch A, Kouroukis C, Crump M, et al.: Phase II trial of bortezomib in mantle cell lymphoma [abstract]. Oral Session. Blood 2004, 104:608.","journal-title":"Blood"},{"key":"53_CR38","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/jco.2006.24.18_suppl.7512","volume":"24","author":"A. Goy","year":"2006","unstructured":"Goy A, Bernstein S, Kahl BS, et al.: Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): results of the PINNACLE study [abstract]. J Clin Oncol Proc ASCO 2006, 24:7512.","journal-title":"J Clin Oncol Proc ASCO"},{"key":"53_CR39","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"R.I. Fisher","year":"2006","unstructured":"Fisher RI, Bernstein S, Kahl BS, et al.: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867\u20134874.","journal-title":"J Clin Oncol"},{"key":"53_CR40","doi-asserted-by":"crossref","first-page":"389a","DOI":"10.1182\/blood.V104.11.389.389","volume":"104","author":"A. Goy","year":"2004","unstructured":"Goy A, Remache Y, Barkoh, et al.: Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-Hodgkin\u2019s lymphoma cells [abstract]. Blood 2004, 104:389a.","journal-title":"Blood"},{"key":"53_CR41","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A. Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, et al.: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 2005, 23:667\u2013675.","journal-title":"J Clin Oncol"},{"key":"53_CR42","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"P.G. Richardson","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S, et al.: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113\u20133120.","journal-title":"J Clin Oncol"},{"key":"53_CR43","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2141.2006.06201.x","volume":"134","author":"J. Gerecitano","year":"2006","unstructured":"Gerecitano J, Goy A, Wright J, et al.: Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 2006, 134:391\u2013398.","journal-title":"Br J Haematol"},{"key":"53_CR44","doi-asserted-by":"crossref","unstructured":"De Vos S, Dakhil SR, McLaughlin P, et al.: Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: final results. Oral Session. Blood 2006; 108.","DOI":"10.1182\/blood.V108.11.694.694"},{"key":"53_CR45","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1200\/jco.2007.25.18_suppl.8051","volume":"25","author":"O. O\u2019Connor","year":"2007","unstructured":"O\u2019Connor O, Hamlin P, Moskowitz C, et al.: Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL). J Clin Oncol 2007, 25:8051.","journal-title":"J Clin Oncol"},{"key":"53_CR46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.leu.2404511","volume":"21","author":"O. Weigert","year":"2007","unstructured":"Weigert O, Pastore A, Rieken M, et al.: Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007, 21:524\u2013528.","journal-title":"Leukemia"},{"key":"53_CR47","doi-asserted-by":"crossref","first-page":"17522","DOI":"10.1200\/jco.2006.24.18_suppl.17522","volume":"24","author":"J. Drach","year":"2006","unstructured":"Drach J, Kaufmann H, Pichelmayer O, et al.: Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma. J Clin Oncol 2006, 24:17522.","journal-title":"J Clin Oncol"},{"key":"53_CR48","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.V106.11.491.491","volume":"104","author":"J. Leonard","year":"2005","unstructured":"Leonard J, Furman R, Feldman E, et al.: Phase I\/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results [abstract]. Blood 2005, 104:491.","journal-title":"Blood"},{"key":"53_CR49","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1200\/jco.2007.25.18_suppl.8010","volume":"25","author":"N. Mounier","year":"2007","unstructured":"Mounier N, Ribrag V, Haioun C, et al.: Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: A randomized phase II trial from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) [abstract]. J Clin Oncol 2007, 25:8010.","journal-title":"J Clin Oncol"},{"key":"53_CR50","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2006.10.2301","volume":"25","author":"K.A. Stewart","year":"2007","unstructured":"Stewart KA, O\u2019Connor OA, Alsina M, et al.: Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: responses in multiple myeloma and Waldenstrom\u2019s macroglobulinemia at well-tolerated doses. J Clin Oncol 2007, 25:8003.","journal-title":"J Clin Oncol"},{"key":"53_CR51","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"T.E. Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I, et al.: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005, 23:5347\u20135356.","journal-title":"J Clin Oncol"},{"key":"53_CR52","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","volume":"108","author":"M. Rudelius","year":"2006","unstructured":"Rudelius M, Pittaluga S, Nishizuka S, et al.: Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006, 108:1668\u20131676.","journal-title":"Blood"},{"key":"53_CR53","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","volume":"12","author":"K.W. Yee","year":"2006","unstructured":"Yee KW, Zeng Z, Konopleva M, et al.: Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006, 12:5165\u20135173.","journal-title":"Clin Cancer Res"},{"key":"53_CR54","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1200\/jco.2005.23.16_suppl.6631","volume":"23","author":"E. Feldman","year":"2005","unstructured":"Feldman E, Giles F, Roboz G, et al.: A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol 2005, 23:6631.","journal-title":"J Clin Oncol"},{"key":"53_CR55","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","volume":"104","author":"H. Kaufmann","year":"2004","unstructured":"Kaufmann H, Raderer M, Wohrer S, et al.: Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma. Blood 2004, 104:2269\u20132271.","journal-title":"Blood"},{"key":"53_CR56","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1182\/blood.V108.11.2482.2482","volume":"108","author":"T.E. Witzig","year":"2006","unstructured":"Witzig TE, Vose JM, Kaplan HP, et al.: Early results from a phase II study of lenalidomide monotherapy in relapsed\/refractory indolent non-Hodgkin\u2019s lymphoma. Blood 2006, 108:2482.","journal-title":"Blood"},{"key":"53_CR57","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1200\/jco.2007.25.18_suppl.8030","volume":"25","author":"M. Wang","year":"2007","unstructured":"Wang M, Fayad L, Hagemeister F, et al.: A phase I\/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed\/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. J Clin Oncol 2007, 25:8030.","journal-title":"J Clin Oncol"},{"key":"53_CR58","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/jco.2007.25.18_suppl.8000","volume":"25","author":"A. Younes","year":"2007","unstructured":"Younes A, Fanale M, Pro B, et al.: A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncology 2007, 25:8000.","journal-title":"J Clin Oncology"},{"key":"53_CR59","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","volume":"24","author":"O.A. O\u2019Connor","year":"2006","unstructured":"O\u2019Connor OA, Heaney ML, Schwartz L, et al.: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24:166\u2013173.","journal-title":"J Clin Oncol"},{"key":"53_CR60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2005.00546.x","volume":"76","author":"U. Heider","year":"2006","unstructured":"Heider U, Kaiser M, Sterz J, et al.: Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 2006, 76:42\u201350.","journal-title":"Eur J Haematol"},{"key":"53_CR61","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","volume":"109","author":"P. Perez-Galan","year":"2007","unstructured":"Perez-Galan P, Roue G, Villamor N, et al.: The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007, 109:4441\u20134449.","journal-title":"Blood"},{"key":"53_CR62","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2003.09.057","volume":"21","author":"C.T. Kouroukis","year":"2003","unstructured":"Kouroukis CT, Belch A, Crump M, et al.: Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:1740\u20131745.","journal-title":"J Clin Oncol"},{"key":"53_CR63","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","volume":"109","author":"J.C. Byrd","year":"2007","unstructured":"Byrd JC, Lin TS, Dalton JT, et al.: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109:399\u2013404.","journal-title":"Blood"},{"key":"53_CR64","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood.V106.11.944.944","volume":"106","author":"T.S. Lin","year":"2005","unstructured":"Lin TS, Fischer B, Moran M, et al.: Flavopiridol, fludarabine and rituximab is a highly active regimen in indolent B-cell lymphoproliferative disorders including mantle cell lymphoma. Blood 2005, 106:944.","journal-title":"Blood"},{"key":"53_CR65","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","volume":"25","author":"M.J. Robertson","year":"2007","unstructured":"Robertson MJ, Kahl BS, Vose JM, et al.: Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007, 25:1741\u20131746.","journal-title":"J Clin Oncol"},{"key":"53_CR66","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","volume":"171","author":"L.V. Pham","year":"2003","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, et al.: Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003, 171:88\u201395.","journal-title":"J Immunol"},{"key":"53_CR67","first-page":"6174","volume":"63","author":"D. Chauhan","year":"2003","unstructured":"Chauhan D, Li G, Shringarpure R, et al.: Blockade of Hsp27 overcomes Bortezomib\/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003, 63:6174\u20136177.","journal-title":"Cancer Res"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-007-0053-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-007-0053-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-007-0053-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T23:55:33Z","timestamp":1587858933000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-007-0053-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,19]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["53"],"URL":"https:\/\/doi.org\/10.1007\/s11912-007-0053-9","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,19]]}}}